Eirik Kjus Aahlin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eirik Kjus Aahlin has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Arthur Revhaug
A Department of Clinical Medicine , UiT The Arctic University of Norway , Tromsø , Norway
3 shared publications - Ewen M. Harrison
Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK
2 shared publications - Kenneth C. H. Fearon
Clinical Surgery, University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, UK
2 shared publications Kristoffer Lassen
Department of GI and HPB surgery University Hospital of Northern Norway Tromsø Norway
2 shared publications- Kristoffer Lassen
Department of GI and HPB Surgery, University Hospital of Northern Norway, Tromsø, 9038, Breivika, Norway
2 shared publications Magnus Nilsson
Department of Clinical Science , Intervention and Technology, Division of Surgery Stockholm , Sweden
2 shared publications
Latest Publications
- Open Access
- 26 February 2026
- Published by Springer Nature in Journal of Imaging Informatics in Medicine
- p. 1-11
The Clinical Utility of Three-Dimensional Liver Modelling: A Multicenter Survey
Pre-operative planning for complex liver surgery is constrained by 2D CT/MRI. Digital 3D liver models (3DL-RL) may improve decision-making, but multicenter evidence on decision-level effects and inter-surgeon variability is limited. A multicenter, case-based survey was conducted among 10 HPB surgeons from all five Norwegian centers. Nine anonymized cases were reviewed in two phases: CT/MRI only, then CT/MRI + 3DL-RL. Fifty-five responses were collected to assess plans, usefulness, and adoption. Agreement and paired comparisons used Krippendorff’s α , Fleiss’ κ , Shapiro–Wilk, Levene’s, paired t , and Wilcoxon tests. 3DL-RL was associated with a significant planning shift (Wilcoxon p = 0.006, r = 0.372). Tumor counts changed in 41/55 (75%), always upward; plans changed in 64% of those versus 25% when counts were unchanged. Frequent modifications included parenchyma-sparing strategies 11/55 (20.0%), switch between surgery and another modality 6/55 (10.9%), extended resection 4/55 (7.3%), and refinements 8/55 (14.5%). Overall inter-surgeon agreement on binary planning remained low (Krippendorff’s α 0.207 CT/MRI vs 0.177 3DL-RL). Per-case anatomical agreement showed that α remains higher in the 3DL-RL group (0.664), with Cohen’s d = 0.571. Across Norwegian HPB units, 3DL-RL meaningfully influences pre-operative planning, often enabling parenchyma-sparing or other targeted changes, while serving as a complementary MDT aid. Variability persists across surgeons, consistent with individualized, precision-oriented decision-making. Larger, prospective, outcome-linked studies and ML-assisted workflows are needed to confirm clinical and economic impact.
- 26 February 2026
- Published by Springer Nature in Journal of Imaging Informatics in Medicine
- p. 1-11
Open AccessThe Clinical Utility of Three-Dimensional Liver Modelling: A Multicenter Survey
Pre-operative planning for complex liver surgery is constrained by 2D CT/MRI. Digital 3D liver models (3DL-RL) may improve decision-making, but multicenter evidence on decision-level effects and inter-surgeon variability is limited. A multicenter, case-based survey was conducted among 10 HPB surgeons from all five Norwegian centers. Nine anonymized cases were reviewed in two phases: CT/MRI only, then CT/MRI + 3DL-RL. Fifty-five responses were collected to assess plans, usefulness, and adoption. Agreement and paired comparisons used Krippendorff’s α , Fleiss’ κ , Shapiro–Wilk, Levene’s, paired t , and Wilcoxon tests. 3DL-RL was associated with a significant planning shift (Wilcoxon p = 0.006, r = 0.372). Tumor counts changed in 41/55 (75%), always upward; plans changed in 64% of those versus 25% when counts were unchanged. Frequent modifications included parenchyma-sparing strategies 11/55 (20.0%), switch between surgery and another modality 6/55 (10.9%), extended resection 4/55 (7.3%), and refinements 8/55 (14.5%). Overall inter-surgeon agreement on binary planning remained low (Krippendorff’s α 0.207 CT/MRI vs 0.177 3DL-RL). Per-case anatomical agreement showed that α remains higher in the 3DL-RL group (0.664), with Cohen’s d = 0.571. Across Norwegian HPB units, 3DL-RL meaningfully influences pre-operative planning, often enabling parenchyma-sparing or other targeted changes, while serving as a complementary MDT aid. Variability persists across surgeons, consistent with individualized, precision-oriented decision-making. Larger, prospective, outcome-linked studies and ML-assisted workflows are needed to confirm clinical and economic impact.
- Open Access
- 15 April 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 540-549
Long-term trends in the clinical management and outcomes of patients with gastroesophageal cancer in Norway
Background and purpose: Gastroesophageal cancers are highly prevalent internationally, with many patients diagnosed with metastatic disease, leading to challenging treatment and poor survival. This study uses real-world evidence from a population-level database to describe demographics, clinical characteristics, initial treatment patterns, and survival for patients with gastroesophageal cancer in Norway. Material and methods: Individual patient data was sourced from the Cancer Registry of Norway for patients diagnosed with oesophageal squamous cell carcinoma (ESCC), oesophageal adenocarcinoma (EAC), gastroesophageal junction cancer (GEJC), and gastric cancer from 2001 to 2021, with follow-up from diagnosis to death or last follow-up. Treatment patterns were captured from 2010 to 2022, defined as curative or palliative based on surgery, chemotherapy, and radiotherapy. Results and interpretation: The cohort included 14,334 Norwegian patients with gastroesophageal cancer; predominantly male, mean age 69–73 years, with a median follow-up of 9–11 months across cancer subtypes. Approximately 40% of patients received curative treatment, and multi-modality treatments increased for EAC, GEJC, and ESCC. Median survival ranged from 6 to 11 months for patients treated palliatively, and 17–95 months for those treated with curative intent. Interestingly, median survival was higher for patients with EAC and GEJC treated with neoadjuvant chemotherapy (86.1 and 75.1 months) versus neoadjuvant chemoradiotherapy (49.1 and 42.1 months), which was confirmed by a multivariate Cox regression model adjusted for age, sex, and disease stage. This study demonstrates that multimodal treatment strategies, consisting of chemotherapy and surgery, may be associated with improved survival outcomes for gastroesophageal cancers. Future studies are required to identify optimum treatment strategies for gastroesophageal cancer subtypes.
- 15 April 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 540-549
Open AccessLong-term trends in the clinical management and outcomes of patients with gastroesophageal cancer in Norway
Background and purpose: Gastroesophageal cancers are highly prevalent internationally, with many patients diagnosed with metastatic disease, leading to challenging treatment and poor survival. This study uses real-world evidence from a population-level database to describe demographics, clinical characteristics, initial treatment patterns, and survival for patients with gastroesophageal cancer in Norway. Material and methods: Individual patient data was sourced from the Cancer Registry of Norway for patients diagnosed with oesophageal squamous cell carcinoma (ESCC), oesophageal adenocarcinoma (EAC), gastroesophageal junction cancer (GEJC), and gastric cancer from 2001 to 2021, with follow-up from diagnosis to death or last follow-up. Treatment patterns were captured from 2010 to 2022, defined as curative or palliative based on surgery, chemotherapy, and radiotherapy. Results and interpretation: The cohort included 14,334 Norwegian patients with gastroesophageal cancer; predominantly male, mean age 69–73 years, with a median follow-up of 9–11 months across cancer subtypes. Approximately 40% of patients received curative treatment, and multi-modality treatments increased for EAC, GEJC, and ESCC. Median survival ranged from 6 to 11 months for patients treated palliatively, and 17–95 months for those treated with curative intent. Interestingly, median survival was higher for patients with EAC and GEJC treated with neoadjuvant chemotherapy (86.1 and 75.1 months) versus neoadjuvant chemoradiotherapy (49.1 and 42.1 months), which was confirmed by a multivariate Cox regression model adjusted for age, sex, and disease stage. This study demonstrates that multimodal treatment strategies, consisting of chemotherapy and surgery, may be associated with improved survival outcomes for gastroesophageal cancers. Future studies are required to identify optimum treatment strategies for gastroesophageal cancer subtypes.
- Open Access
- 21 May 2024
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 144 (7)
Sanering av gallesteiner i ett steg
21.05.2024: Invitert kommentar - Sanering av konkrementer i galleblæren og gallegangen i én prosedyre kan spare tid og ressurser, både for pasient og helsevesen.
- 21 May 2024
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 144 (7)
Open AccessSanering av gallesteiner i ett steg
21.05.2024: Invitert kommentar - Sanering av konkrementer i galleblæren og gallegangen i én prosedyre kan spare tid og ressurser, både for pasient og helsevesen.
- Open Access
- 16 February 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 37 (6)
Randomized controlled trial of nasogastric tube use after esophagectomy: study protocol for the kinetic trial
Summary: Esophagectomy is a complex and complication laden procedure. Despite centralization, variations in perioparative strategies reflect a paucity of evidence regarding optimal routines. The use of nasogastric (NG) tubes post esophagectomy is typically associated with significant discomfort for the patients. We hypothesize that immediate postoperative removal of the NG tube is non-inferior to current routines. All Nordic Upper Gastrointestinal Cancer centers were invited to participate in this open-label pragmatic randomized controlled trial (RCT). Inclusion criteria include resection for locally advanced esophageal cancer with gastric tube reconstruction. A pretrial survey was undertaken and was the foundation for a consensus process resulting in the Kinetic trial, an RCT allocating patients to either no use of a NG tube (intervention) or 5 days of postoperative NG tube use (control) with anastomotic leakage as primary endpoint. Secondary endpoints include pulmonary complications, overall complications, length of stay, health related quality of life. A sample size of 450 patients is planned (Kinetic trial: https://www.isrctn.com/ISRCTN39935085). Thirteen Nordic centers with a combined catchment area of 17 million inhabitants have entered the trial and ethical approval was granted in Sweden, Norway, Finland, and Denmark. All centers routinely use NG tube and all but one center use total or hybrid minimally invasive-surgical approach. Inclusion began in January 2022 and the first annual safety board assessment has deemed the trial safe and recommended continuation. We have launched the first adequately powered multi-center pragmatic controlled randomized clinical trial regarding NG tube use after esophagectomy with gastric conduit reconstruction.
- 16 February 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 37 (6)
Open AccessRandomized controlled trial of nasogastric tube use after esophagectomy: study protocol for the kinetic trial
Summary: Esophagectomy is a complex and complication laden procedure. Despite centralization, variations in perioparative strategies reflect a paucity of evidence regarding optimal routines. The use of nasogastric (NG) tubes post esophagectomy is typically associated with significant discomfort for the patients. We hypothesize that immediate postoperative removal of the NG tube is non-inferior to current routines. All Nordic Upper Gastrointestinal Cancer centers were invited to participate in this open-label pragmatic randomized controlled trial (RCT). Inclusion criteria include resection for locally advanced esophageal cancer with gastric tube reconstruction. A pretrial survey was undertaken and was the foundation for a consensus process resulting in the Kinetic trial, an RCT allocating patients to either no use of a NG tube (intervention) or 5 days of postoperative NG tube use (control) with anastomotic leakage as primary endpoint. Secondary endpoints include pulmonary complications, overall complications, length of stay, health related quality of life. A sample size of 450 patients is planned (Kinetic trial: https://www.isrctn.com/ISRCTN39935085). Thirteen Nordic centers with a combined catchment area of 17 million inhabitants have entered the trial and ethical approval was granted in Sweden, Norway, Finland, and Denmark. All centers routinely use NG tube and all but one center use total or hybrid minimally invasive-surgical approach. Inclusion began in January 2022 and the first annual safety board assessment has deemed the trial safe and recommended continuation. We have launched the first adequately powered multi-center pragmatic controlled randomized clinical trial regarding NG tube use after esophagectomy with gastric conduit reconstruction.
- Open Access
- 6 June 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (8) , 877-879
Stepping up the management of anastomotic leaks after oesophagectomy: getting a feel through less invasive tentacles
Oesophageal anastomoses after oesophagectomy are prone to leakage owing to mechanical issues, and the restricted blood supply after mobilization of the oesophageal substitute from the abdomen to the mediastinum or neck. This also challenges healing of any anastomotic defect. The reported rates of leakage range from less than 5 per cent to more than 30 per cent1. Oesophageal anastomotic leaks and pulmonary complications have been suggested to have the strongest associations with postoperative mortality, prolonged hospital stay, need for reoperation, and readmissions2. Furthermore, leaks may affect long-term outcome and survival3,4. Preventive measures include dedicated surgical technique, procedural proficiency, standardized clinical pathways, and selection of patients for surgery5.
- 6 June 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (8) , 877-879
Open AccessStepping up the management of anastomotic leaks after oesophagectomy: getting a feel through less invasive tentacles
Oesophageal anastomoses after oesophagectomy are prone to leakage owing to mechanical issues, and the restricted blood supply after mobilization of the oesophageal substitute from the abdomen to the mediastinum or neck. This also challenges healing of any anastomotic defect. The reported rates of leakage range from less than 5 per cent to more than 30 per cent1. Oesophageal anastomotic leaks and pulmonary complications have been suggested to have the strongest associations with postoperative mortality, prolonged hospital stay, need for reoperation, and readmissions2. Furthermore, leaks may affect long-term outcome and survival3,4. Preventive measures include dedicated surgical technique, procedural proficiency, standardized clinical pathways, and selection of patients for surgery5.
- Open Access
- 24 May 2022
- Published by Elsevier in The Lancet Global Health
- Vol. 10 (7) , e1003-e1011
Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study
- 24 May 2022
- Published by Elsevier in The Lancet Global Health
- Vol. 10 (7) , e1003-e1011
Open AccessEffects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study
- 4 March 2019
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 106 (6) , 756-764
Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation
Background: Multidisciplinary team (MDT) meetings have been adopted widely to ensure optimal treatment for patients with cancer. Agreements in tumour staging, resectability assessments and treatment allocation between different MDTs were assessed. Methods: Of all patients referred to one hospital, 19 patients considered to have non-metastatic pancreatic cancer for evaluation were selected randomly for a multicentre study of MDT decisions in seven units across Northern Europe. Anonymized clinical information and radiological images were disseminated to the MDTs. All patients were reviewed by the MDTs for radiological T, N and M category, resectability assessment and treatment allocation. Each MDT was blinded to the decisions of other teams. Agreements were expressed as raw percentages and Krippendorff's α values, both with 95 per cent confidence intervals. Results: A total of 132 evaluations in 19 patients were carried out by the seven MDTs (1 evaluation was excluded owing to technical problems). The level of agreement for T, N and M categories ranged from moderate to near perfect (46·8, 61·1 and 82·8 per cent respectively), but there was substantial variation in assessment of resectability; seven patients were considered to be resectable by one MDT but unresectable by another. The MDTs all agreed on either a curative or palliative strategy in less than half of the patients (9 of 19). Only fair agreement in treatment allocation was observed (Krippendorff's α 0·31, 95 per cent c.i. 0·16 to 0·45). There was a high level of agreement in treatment allocation where resectability assessments were concordant. Conclusion: Considerable disparities in MDT evaluations of patients with pancreatic cancer exist, including substantial variation in resectability assessments.
- 4 March 2019
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 106 (6) , 756-764
Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation
Background: Multidisciplinary team (MDT) meetings have been adopted widely to ensure optimal treatment for patients with cancer. Agreements in tumour staging, resectability assessments and treatment allocation between different MDTs were assessed. Methods: Of all patients referred to one hospital, 19 patients considered to have non-metastatic pancreatic cancer for evaluation were selected randomly for a multicentre study of MDT decisions in seven units across Northern Europe. Anonymized clinical information and radiological images were disseminated to the MDTs. All patients were reviewed by the MDTs for radiological T, N and M category, resectability assessment and treatment allocation. Each MDT was blinded to the decisions of other teams. Agreements were expressed as raw percentages and Krippendorff's α values, both with 95 per cent confidence intervals. Results: A total of 132 evaluations in 19 patients were carried out by the seven MDTs (1 evaluation was excluded owing to technical problems). The level of agreement for T, N and M categories ranged from moderate to near perfect (46·8, 61·1 and 82·8 per cent respectively), but there was substantial variation in assessment of resectability; seven patients were considered to be resectable by one MDT but unresectable by another. The MDTs all agreed on either a curative or palliative strategy in less than half of the patients (9 of 19). Only fair agreement in treatment allocation was observed (Krippendorff's α 0·31, 95 per cent c.i. 0·16 to 0·45). There was a high level of agreement in treatment allocation where resectability assessments were concordant. Conclusion: Considerable disparities in MDT evaluations of patients with pancreatic cancer exist, including substantial variation in resectability assessments.
- Open Access
- 1 January 2017
- Published by Wiley in JCSM Clinical Reports
- Vol. 2 (1) , 1-7
Body composition indices and tissue loss in patients with resectable gastric adenocarcinoma
Background: Body composition analyses from computed tomography (CT) scans have been used to assess cachexia in cancer patients. We investigated body composition indices, tissue change and treatment outcome in patients with resectable gastric adenocarcinoma. Methods: A cohort analysis of all patients treated with curative intent for gastric adenocarcinoma in two Scandinavian university hospitals from 2008-2011 was performed (n=137). Body composition analyses were performed on CT images taken for routine diagnostics and staging. Both preoperative single scans and repeat CT examinations were analyzed. Results: Perioperative chemotherapy was given to 58 (42.3%) patients. Forty patients (29.2%) suffered severe postoperative complications and 70 (51.1%) patients died within three years. There was a significant reduction in patients’ lean tissue during neoadjuvant chemotherapy (p=0.001). Poorer survival was observed in patients with preoperative skeletal muscle tissue index within the lowermost quartile, independent of tumor characteristics and neoadjuvant treatment (HR=1.91, 95% CI 1.11-3.28, p=0.019). Conclusions: Patients lost lean tissue during neoadjuvant treatment for gastric adenocarcinoma. Low preoperative skeletal muscle index was associated with poorer survival.
- 1 January 2017
- Published by Wiley in JCSM Clinical Reports
- Vol. 2 (1) , 1-7
Open AccessBody composition indices and tissue loss in patients with resectable gastric adenocarcinoma
Background: Body composition analyses from computed tomography (CT) scans have been used to assess cachexia in cancer patients. We investigated body composition indices, tissue change and treatment outcome in patients with resectable gastric adenocarcinoma. Methods: A cohort analysis of all patients treated with curative intent for gastric adenocarcinoma in two Scandinavian university hospitals from 2008-2011 was performed (n=137). Body composition analyses were performed on CT images taken for routine diagnostics and staging. Both preoperative single scans and repeat CT examinations were analyzed. Results: Perioperative chemotherapy was given to 58 (42.3%) patients. Forty patients (29.2%) suffered severe postoperative complications and 70 (51.1%) patients died within three years. There was a significant reduction in patients’ lean tissue during neoadjuvant chemotherapy (p=0.001). Poorer survival was observed in patients with preoperative skeletal muscle tissue index within the lowermost quartile, independent of tumor characteristics and neoadjuvant treatment (HR=1.91, 95% CI 1.11-3.28, p=0.019). Conclusions: Patients lost lean tissue during neoadjuvant treatment for gastric adenocarcinoma. Low preoperative skeletal muscle index was associated with poorer survival.
- Open Access
- 8 July 2016
- Published by SAGE Publications in Scandinavian Journal of Surgery
- Vol. 106 (1) , 40-46
Health-Related Quality of Life, Cachexia and Overall Survival After Major Upper Abdominal Surgery: A Prospective Cohort Study
Background and Aims: Major upper abdominal surgery is often associated with reduced health-related quality of life and reduced survival. Patients with upper abdominal malignancies often suffer from cachexia, represented by preoperative weight loss and sarcopenia (low skeletal muscle mass) and this might affect both health-related quality of life and survival. We aimed to investigate how health-related quality of life is affected by cachexia and how health-related quality of life relates to long-term survival after major upper abdominal surgery. Materials and Methods: From 2001 to 2006, 447 patients were included in a Norwegian multicenter randomized controlled trial in major upper abdominal surgery. In this study, six years later, these patients were analyzed as a single prospective cohort and survival data were retrieved from the National Population Registry. Cachexia was derived from patient-reported preoperative weight loss and sarcopenia as assessed from computed tomography images taken within three months preoperatively. In the original trial, self-reported health-related quality of life was assessed preoperatively at trial enrollment and eight weeks postoperatively with the health-related quality of life questionnaire Short Form 36. Results: A majority of the patients experienced improved mental health-related quality of life and, to a lesser extent, deteriorated physical health-related quality of life following surgery. There was a significant association between preoperative weight loss and reduced physical health-related quality of life. No association between sarcopenia and health-related quality of life was observed. Overall survival was significantly associated with physical health-related quality of life both pre- and postoperatively, and with postoperative mental health-related quality of life. The association between health-related quality of life and survival was particularly strong for postoperative physical health-related quality of life. Conclusion: Postoperative physical health-related quality of life strongly correlates with overall survival after major upper abdominal surgery.
- 8 July 2016
- Published by SAGE Publications in Scandinavian Journal of Surgery
- Vol. 106 (1) , 40-46
Open AccessHealth-Related Quality of Life, Cachexia and Overall Survival After Major Upper Abdominal Surgery: A Prospective Cohort Study
Background and Aims: Major upper abdominal surgery is often associated with reduced health-related quality of life and reduced survival. Patients with upper abdominal malignancies often suffer from cachexia, represented by preoperative weight loss and sarcopenia (low skeletal muscle mass) and this might affect both health-related quality of life and survival. We aimed to investigate how health-related quality of life is affected by cachexia and how health-related quality of life relates to long-term survival after major upper abdominal surgery. Materials and Methods: From 2001 to 2006, 447 patients were included in a Norwegian multicenter randomized controlled trial in major upper abdominal surgery. In this study, six years later, these patients were analyzed as a single prospective cohort and survival data were retrieved from the National Population Registry. Cachexia was derived from patient-reported preoperative weight loss and sarcopenia as assessed from computed tomography images taken within three months preoperatively. In the original trial, self-reported health-related quality of life was assessed preoperatively at trial enrollment and eight weeks postoperatively with the health-related quality of life questionnaire Short Form 36. Results: A majority of the patients experienced improved mental health-related quality of life and, to a lesser extent, deteriorated physical health-related quality of life following surgery. There was a significant association between preoperative weight loss and reduced physical health-related quality of life. No association between sarcopenia and health-related quality of life was observed. Overall survival was significantly associated with physical health-related quality of life both pre- and postoperatively, and with postoperative mental health-related quality of life. The association between health-related quality of life and survival was particularly strong for postoperative physical health-related quality of life. Conclusion: Postoperative physical health-related quality of life strongly correlates with overall survival after major upper abdominal surgery.
- Open Access
- 18 May 2016
- Published by Springer Nature in BMC Surgery
- Vol. 16 (1) , 32
Major postoperative complications are associated with impaired long-term survival after gastro-esophageal and pancreatic cancer surgery: a complete national cohort study
Some studies have reported an association between complications and impaired long-term survival after cancer surgery. We aimed to investigate how major complications are associated with overall survival after gastro-esophageal and pancreatic cancer surgery in a complete national cohort. All esophageal-, gastric- and pancreatic resections performed for cancer in Norway between January 1, 2008, and December 1, 2013 were identified in the Norwegian Patient Registry together with data concerning major postoperative complications and survival. When emergency cases were excluded, there were 1965 esophageal-, gastric- or pancreatic resections performed for cancer in Norway between 1 January 2008, and 1 December 2013. A total of 248 patients (12.6 %) suffered major postoperative complications. Complications were associated both with increased early (90 days) mortality (OR = 4.25, 95 % CI = 2.78–6.50), and reduced overall survival when patients suffering early mortality were excluded (HR = 1.23, 95 % CI = 1.01–1.50). Major postoperative complications are associated with impaired long-term survival after gastro-esophageal and pancreatic cancer surgery.
- 18 May 2016
- Published by Springer Nature in BMC Surgery
- Vol. 16 (1) , 32
Open AccessMajor postoperative complications are associated with impaired long-term survival after gastro-esophageal and pancreatic cancer surgery: a complete national cohort study
Some studies have reported an association between complications and impaired long-term survival after cancer surgery. We aimed to investigate how major complications are associated with overall survival after gastro-esophageal and pancreatic cancer surgery in a complete national cohort. All esophageal-, gastric- and pancreatic resections performed for cancer in Norway between January 1, 2008, and December 1, 2013 were identified in the Norwegian Patient Registry together with data concerning major postoperative complications and survival. When emergency cases were excluded, there were 1965 esophageal-, gastric- or pancreatic resections performed for cancer in Norway between 1 January 2008, and 1 December 2013. A total of 248 patients (12.6 %) suffered major postoperative complications. Complications were associated both with increased early (90 days) mortality (OR = 4.25, 95 % CI = 2.78–6.50), and reduced overall survival when patients suffering early mortality were excluded (HR = 1.23, 95 % CI = 1.01–1.50). Major postoperative complications are associated with impaired long-term survival after gastro-esophageal and pancreatic cancer surgery.